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The new US precision medicine initiative1 has been made possible by improvement and 
price reduction in genome sequencing, as well as advances in multiple sectors of 
biotechnology. The initiative includes 2 components: a focus on cancer intended to spur 
development of new targeted cancer treatments, and a proposal for establishing a national 
cohort of at least 1 million people to explore genetic and environmental determinants of 
health and disease. The success of this initiative requires a public health perspective to help 
ensure generalizability, assess methods of implementation, focus on prevention, and provide 
an appropriate balance between generation of long-term knowledge and short-term health 
gains.
Although precision medicine focuses on individualized care, it is impossible to infer 
causality by working from individual observations. Data from large numbers of people are 
required to identify characteristics, including genetic markers predictive of treatment 
response. Moreover, from a public health perspective, collecting information from large 
numbers of people is far more informative when these people reflect the diversity of the 
underlying population. Using convenience samples—ie, collected without regard to 
important factors such as race and ethnicity, age, and sex—can lead to substantial biases and 
nongeneralizable predictions. This is especially true in genomics because different ancestry 
may result in differing genomic architecture of health and disease states.
The concept of precision prevention may therefore be valuable for efficiently 
targeting preventive strategies to the specific subsets of a population that will 
derive maximal benefit.
Precision medicine currently focuses largely on treatment, but decades of successful public 
health interventions suggest prevention warrants a robust focus. Although treatment can 
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reduce morbidity and improve quality of life for sick individuals, disease prevention is 
important for the entire population. Risks for various diseases vary among people based on 
genetic and environmental factors. The concept of precision prevention may therefore be 
valuable for efficiently targeting preventive strategies to the specific subsets of a population 
that will derive maximal benefit. For example, improving access to smoking cessation 
assistance is a component of the highly successful public health efforts that have resulted in 
reductions in smoking over the past few decades. Recent data suggest that using genetically 
informed biomarkers of the speed with which people metabolize nicotine2 could lead to 
personalized smoking cessation. Another example of precision prevention is changes in 
recommended screening schedules for people at increased risk of cancer, identified either by 
acquisition of family health history or through detection of those individuals who carry 
pathogenic mutations in high-risk cancer genes.
The proposed long-term investment in precision medicine comes at a time of increasing 
fiscal restraint and widespread recognition that the US health care system underperforms in 
terms of health outcomes. Therefore, in addition to long-term knowledge acquisition, it is 
imperative that this investment also generates early measurable health benefits such as those 
that could be derived from the million-person cohort. At a recent National Institutes of 
Health workshop about the proposed national cohort,3 early success was described using a 
hypothetical 50-year-old woman with type 2 diabetes and suboptimal glucose control. The 
patient had her genome sequenced and she had a tiny chip implanted to track her glucose 
level. Using these data, she changed her diet and her medicine dose schedule. Based on 
novel findings from the cohort, her physician switched her to a new molecularly targeted 
drug.
However, to realize improved diabetes control based on precision approaches, researchers 
will not only have to make new discoveries but would also need to conduct follow-up 
studies including randomized trials. A more realistic scenario for near-term health benefit 
derived from this large cohort is to assess implementation of already proven interventions, 
especially if the cohort adequately represents various populations including minority racial 
and ethnic groups and underserved populations. Using the example of the woman with type 
2 diabetes, finding and enrolling people with prediabetes into diabetes prevention programs 
could help prevent the onset of overt disease. Potentially, millions of people in the United 
States could benefit from such interventions but do not know they have prediabetes. The 
cohort could assess how to identify thousands of persons with prediabetes (through standard 
non genomic tests) and connect them with available interventions.
A unique feature of the proposed cohort is whole-genome sequencing of the participants.4, 5 
Although this will inevitably lead to numerous discoveries and possible interventions, it will 
take time to yield dividends. In the meantime, there is a real opportunity for near-term 
benefit by focusing on conditions for which evidence-based applications are already 
available. The Centers for Disease Control and Prevention has created a 3-tier classification 
schema of genomic applications based on the methods of evidence-based medicine.5 
Similarly, a “binning” strategy for the human genome was proposed based on clinical 
validity and utility of genes and genomic variants.6 Tier 1 (bin 1) genes and their variants 
are those with sufficient evidence for clinical validity and clinical utility to provide 
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meaningful and actionable information to consumers and health care practitioners. Tier 2 
(bin 2) genes and their variants are those with established evidence of validity but 
insufficient evidence of utility to support a recommendation for medical action. Tier 3 (bin 
3) genes and their variants are those with either sufficient evidence for a lack of utility or 
presence of clear risk of harm, or those with insufficient evidence for both validity and 
utility.
Adoption of tier 1 applications in the proposed million-person cohort could provide a path 
toward obtaining immediate benefits for thousands of participants and their families. 
Examples of tier 1 conditions for which preventive interventions are already available 
among persons with a predisposing mutation include hereditary breast and ovarian cancer 
syndrome (BRCA mutations), Lynch syndrome (associated with increased risk of colorectal 
cancer), and familial hypercholesterolemia. An estimated 2 million people in the United 
States have one of these conditions and most are not aware of their risk for cancer or heart 
disease. Once these individuals are identified, evidence-based interventions are available 
that can reduce their risk of adverse health outcomes. The challenges include how to best 
obtain consent, educate, identify, and deliver results to such individuals in the population 
because the implementation of any public health measure also carries risks and costs, as well 
as potential benefits. For example, although most would agree that identifying individuals at 
high risk of a preventable condition is desirable, important questions, such as the true 
penetrance of these conditions when ascertained via a population-based approach, remain to 
be answered.
This cohort of a million or more people would be expected to include many thousands of 
undiagnosed, unrecognized patients with a high risk for breast/ovarian cancer, colorectal 
cancer, or coronary heart disease, identified through genomic sequencing. If identified and 
properly educated, these individuals and their relatives could leverage established 
interventions to reduce their risk—an immediate potential benefit from this endeavor. Just as 
important, the cohort could inform many critical questions that need to be answered before 
implementing genomics at the population level. Other potential targets may include a 
carefully selected subset of highly actionable genes that the American College of Medical 
Genetics and Genomics7 has recommended be analyzed when individuals undergo genome-
scale sequencing for other reasons.
Important ingredients for optimal success of a large-scale cohort include engaging and 
educating the public, policy makers, and patients about precision medicine; ensuring access 
to validated discoveries; and measuring and addressing disparities. Other key components 
include linking health care and public health systems (eg, using state-based cancer registries 
to identify cases of cancers with specific genetic mutations) and developing population-level 
metrics for monitoring (eg, National Precision Medicine Objectives, similar to the US 
Healthy People 2020 objectives used to track progress in health care and prevention for 
decades).8
In summary, a large, diverse and inclusive, precision medicine cohort could eventually allow 
the United States to reap long-term benefits from a better understanding of human disease. 
Additionally, in the short term, there exists an immediate opportunity to deploy genomic 
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information for prevention and health care services, conduct applied research in 
communication and behavioral sciences, and pursue rigorous outcome research that could 
potentially benefit patients, families, and communities. A continued dialogue among 
initiative stakeholders will be necessary to balance such near-term potentials with the long-
term goal of knowledge generation.
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